Skip to main navigation
Skip to main content
Skip to Footer
Google Tag Manager
US
Novartis site directory
Our Products
US Products By Brand
Patient Assistance
Product Portfolio
Our Process
Therapeutic Areas
Product Related Issues
About Us
Novartis US at a Glance
Who We Are
Diversity and Inclusion
Our Leadership
Supplier Diversity
Research
Contact Us
Corporate Responsibility
Novartis in Society US Reports
Corporate Citizenship
Business Conduct
Corporate Integrity Agreement
Payments to HCPs & HCOs
Post-Marketing Commitments
Enhanced Verification Request
News
News Archive
Statements
Stories
US Media Contacts
Novartis US COVID-19 Initiatives
Careers
Careers Search
Working at Novartis
Employee Benefits
Awards & Recognition
NIBR Careers Frequently Asked Questions
Search
News Archive
Advanced Search
Basic Search
From Date:
To Date:
Show:
All
Media Releases
Stories
Filter By
2020
December
Media Release
/
Dec 01, 2020
Novartis announces FDA approval of Xolair® (omalizumab) for adults with nasal polyps
Read More
November
Media Release
/
Nov 19, 2020
New data at ASH to reinforce breadth of Novartis hematology portfolio across multiple blood cancers and serious hematologic diseases
Read More
Media Release
/
Nov 13, 2020
New Novartis analyses for investigational inclisiran demonstrate consistently effective and sustained LDL-C reduction at month 17, regardless of age and gender
Read More
Media Release
/
Nov 05, 2020
Novartis Cosentyx® shows early synovitis reduction in patients with psoriatic arthritis in first-of-its-kind study
Read More
October
Media Release
/
Oct 05, 2020
Novartis STEP Program™ awards nearly $375,000 to patient advocacy organizations for their innovative solutions in biomarker testing; now accepting proposals for caregiving in cancer and certain blood disorders
Read More
Media Release
/
Oct 03, 2020
Novartis announces five-year data that reinforce the safety and efficacy profile of Aimovig® (erenumab-aooe) in adult patients with episodic migraine
Read More
September
Media Release
/
Sep 16, 2020
Novartis US Foundation commits $25M to improve health equity by reducing health disparities in the US
Read More
Media Release
/
Sep 11, 2020
Novartis presents data at ACTRIMS-ECTRIMS on the effects of treatment with Mayzent® (siponimod) studied on disability progression and cognitive processing speed in patients with progressing relapsing multiple sclerosis
Read More
Media Release
/
Sep 11, 2020
Novartis presents data at ACTRIMS-ECTRIMS for Kesimpta® (ofatumumab) in newly diagnosed treatment-naïve adults with relapsing multiple sclerosis
Read More
Search Results Navigation
Current page
1
of 5
Page
2
of 5
Page
3
of 5
Page
4
of 5
Page
5
of 5
…
Next page
next ›
Last page
last »
Share
Email
Jump to Comments
Print
Save
Related Links
Novartis joins the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative
You are here
Home
›
News
